Internal Medicine, Rheumatology · Durant, OK
NPI
1972098242
Since 2018
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1801 Chukka Hina
Durant, OK, 74701
Phone (918) 567-7140
Groups this clinician bills Medicare through
Medicare paid, 2024
$23K
323 services
Medicare patients, 2024
124
Average age 67
Drug cost, 2024
$1.5M
971 prescriptions
Company payments, 2024
$18.55
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Iman Qaiser was code 99214 (office e&m - established), 187 times for 100 patients. In total Iman Qaiser billed 323 services in 17 codes, and Medicare paid $23K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-07-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 187 | 100 | $65.21 | $12K |
| 99215 Office E&M - Established | Office | 47 | 37 | $105.44 | $4,956 |
| 99205 Office E&M - New | Office | 22 | 22 | $134.85 | $2,967 |
| 20610 Joint Injection | Office | 14 | 11 | $28.71 | $402 |
| 99204 Office E&M - New | Office | 11 | 11 | $89.46 | $984 |
By year: 2023 $5,066 for 85 services; 2024 $23K for 323 services.
Medicare prescription drug claims, 2024
In 2024, the drug Iman Qaiser prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 82 prescriptions and refills. In total Iman Qaiser wrote 971 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 82 | 87 | 15 | $1,938 |
| Prednisone Generic | 79 | 81 | Under 11 | $946 |
| Sulfasalazine Generic | 76 | 78 | 12 | $1,649 |
| Humira(Cf) Pen Adalimumab | 74 | 75 | 13 | $638K |
| Diclofenac Sodium Generic | 71 | 71 | 26 | $320 |
| Enbrel Sureclick Etanercept | 51 | 51 | Under 11 | $399K |
| Hadlima(Cf) Pushtouch Adalimumab-Bwwd | 50 | 52 | 11 | $74K |
| Leflunomide Generic | 45 | 45 | Under 11 | $3,984 |
| Hydroxychloroquine Sulfate Generic | 31 | 33 | 11 | $773 |
| Actemra Actpen Tocilizumab | 29 | 29 | Under 11 | $140K |
| Pilocarpine Hcl Generic | 29 | 29 | Under 11 | $1,474 |
| Colchicine Generic | 29 | 29 | Under 11 | $385 |
| Meloxicam Generic | 25 | 29 | 11 | $84.05 |
| Otrexup Methotrexate/Pf | 25 | 25 | Under 11 | $20K |
| Alendronate Sodium Generic | 24 | 28 | Under 11 | $375 |
Brand drugs: 430 claims; generic drugs: 541 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Iman Qaiser $18.55 ($18.55 in general payments such as food, travel and fees) from 1 company. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $18.55.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18.55 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.